Synthetic 29-amino acid GHRH analog, the first FDA-approved GH-releasing peptide (Geref®). Stimulates natural pulsatile GH secretion from the pituitary.
Last Updated: May 2026
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of human GHRH — the minimum sequence required for full GHRH receptor activation. It was the first FDA-approved GH-releasing peptide, marketed as Geref for pediatric growth hormone deficiency before being discontinued from the US market in 2008 for commercial (not safety) reasons. Sermorelin is currently available through compounding pharmacies in the US and as a research-use-only compound from third-party laboratories.
Sermorelin is the synthetic first-29-amino-acid fragment of human GHRH, which retains full GHRH receptor agonist activity and stimulates pituitary growth hormone release. It is the parent compound from which mod GRF 1-29 and the CJC-1295 family were derived through stability-enhancing modifications. Sermorelin itself has a short half-life (~10–20 minutes) and is degraded by DPP-4, requiring daily subcutaneous dosing. Evidence level: Human RCT (Phase 3 for pediatric GH deficiency).
Sermorelin received FDA approval as Geref in 1990 based on pivotal pediatric GH deficiency trials demonstrating improved growth velocity and IGF-1 elevation. Adult use, while not FDA-approved, is well-characterized in pharmacokinetic and pharmacodynamic studies — daily evening administration reliably produces nocturnal GH pulses approximating physiological patterns. The Geref product was discontinued from the US market in 2008 for commercial reasons; sermorelin remains available through compounding pharmacies and research-grade suppliers. Evidence level: Human RCT (Phase 3, pediatric); PK/PD extensive (adult).
Sermorelin is the reference GHRH(1-29) analog from which more-stable analogs were developed. Tesamorelin adds N-terminal modification for DPP-4 resistance and extended action; mod GRF 1-29 adds four amino acid substitutions for stability; CJC-1295 with DAC adds an albumin-binding tether for 6–8 day half-life.
| GHRH analog | Sequence | Stability modification | Half-life | FDA status |
|---|---|---|---|---|
| Sermorelin | GHRH(1-29) native | None | ~10–20 min | FDA-approved (Geref, discontinued) |
| Mod GRF 1-29 | GHRH(1-29) + 4 substitutions | Stability substitutions | ~30 min | Research-use |
| Tesamorelin | GHRH(1-44) + hexenoic acid | DPP-4 resistance | ~26 min | FDA-approved (Egrifta) |
| CJC-1295 with DAC | GHRH(1-29) + DAC tether | Albumin binding | ~6–8 days | Research-use |
Sermorelin's side effect profile in pediatric Geref trials was mild — injection-site reactions, occasional flushing, transient headache. Cortisol and prolactin effects are minimal (it is a pure GHRH analog, not a ghrelin-receptor GHS). IGF-1 elevation is dose-dependent and modest, with monitoring recommended for sustained administration. Long-term safety in adults at research-use dosing is less characterized than in pediatric Geref use. Evidence level: Human Phase 3 safety data (pediatric); adult long-term less characterized.
Sermorelin was FDA-approved as Geref (1990, discontinued from US market 2008 for commercial reasons) for pediatric growth hormone deficiency. It is currently available in the US through compounding pharmacies under 503A and 503B regulations, and as research-grade material from third-party laboratories. The compounding pharmacy pathway depends on regulatory status that has been in flux during 2024–2026. Current status in FDA peptide regulation 2025–2026 timeline.
Because sermorelin is widely sold by both compounding pharmacies and research-grade suppliers — and the quality assurance between the two pathways differs substantially. Compounding pharmacy product carries pharmacy-grade QA; research-grade material varies by vendor. Independent HPLC purity testing and mass spectrometry identity confirmation are essential for research-grade material. Guidance in how-to-test-peptides hub.
Peptigrity purchases sermorelin vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. Peptigrity publishes independent sermorelin test results in the table above. For COA interpretation, see red flags in peptide certificates of analysis.
Sermorelin is available legally through US compounding pharmacies (503A/503B) when prescribed by a licensed physician, and is legal to purchase as a research chemical from third-party laboratories for laboratory use only. The compounding pathway has been subject to FDA regulatory action during 2024–2026. Country breakdown in peptide legal status guide.
Geref was withdrawn from the US market in 2008 for commercial reasons — the pediatric GH deficiency market shifted toward recombinant human growth hormone (rhGH) products, and Geref's market share did not justify continued production. The withdrawal was not safety-related; sermorelin's safety profile remained favorable.
Mod GRF 1-29 is sermorelin (GHRH(1-29)) with four amino acid substitutions for stability and DPP-4 resistance. The stabilized analog has slightly longer half-life and is more commonly used in research protocols where extended GH stimulation is desired. They are not interchangeable as products though pharmacologically related.
No. Peptigrity is an independent review platform, not a medical authority. The Geref pediatric dose was 30 mcg/kg subcutaneous daily; adult use is not FDA-approved and protocols vary. Anyone considering sermorelin should consult a licensed physician.
Sermorelin and other GHRH analogs are on the WADA Prohibited List (Section S2 — Peptide Hormones) and competitive athletes face sanctions for use. Detection methods for GHRH analogs in anti-doping testing have improved. For drug-testing context, see do peptides show up on drug tests.
This section is for educational and informational purposes only and does not constitute medical advice. Sermorelin is FDA-approved (Geref, discontinued from US market) but research-grade material sold for laboratory use is not the prescription product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.